Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

NCT05216120 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped enrollment challenges

Conditions

Pancreas Cancer

Interventions

DRUG: Pemigatinib 4.5 MG

Sponsor

HonorHealth Research Institute

Collaborators

[object Object]